ARS Pharmaceuticals Nears Profitability Timeline While Prescription Growth Masks Cost Questions

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

ARS Pharmaceuticals typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 8.49% and Day +1 move of 4.03%. The stock has demonstrated particularly dramatic swings, including a 22.83% surge on Day 0 in March 2025 followed by a 13.63% reversal the next day, and a 15.23% decline in November 2024. Most recently, the May 2026 earnings triggered a 6.49% Day 0 decline followed by a more modest 1.68% Day +1 drop.

The average Day 0 trading range of 14.82% indicates substantial intraday volatility as investors position ahead of results, while the Day +1 range of 8.77% shows continued uncertainty in the immediate aftermath. The pattern suggests SPRY tends to see its largest moves on the day following earnings (Day +1 for after-hours reporters), with follow-through action often extending the initial reaction rather than reversing it. Investors should prepare for potential double-digit percentage swings in either direction based on whether the company can break its recent pattern of disappointing results.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 16.86% through the August 21 expiration, significantly higher than the stock's average historical Day 0 move of 8.49% and even exceeding the average Day 0 range of 14.82%. This elevated implied volatility of 116.19% suggests options traders are anticipating a more dramatic reaction than typical, possibly reflecting heightened uncertainty around the company's ability to demonstrate improving fundamentals after several quarters of disappointments.

Part 3: What Analysts Are Saying

Analysts maintain a bullish consensus on ARS Pharmaceuticals despite recent stock weakness, with an average rating of 4.60 out of 5.0 (Strong Buy territory). The current breakdown shows 4 Strong Buy ratings and 1 Hold, with no sell recommendations. The average price target of $28.67 implies substantial 374% upside from the current price of $6.05, with individual targets ranging from $24.00 to $32.00.

Analyst sentiment has remained unchanged over the past month, with the rating distribution holding steady at 4 Strong Buys and 1 Hold. This stability suggests the analyst community is maintaining conviction in the long-term thesis despite near-term execution challenges and the stock's steep decline. The wide gap between current trading levels and price targets indicates analysts view the recent selloff as overdone relative to Neffy's commercial potential and the company's market opportunity in needle-free epinephrine delivery.

The consensus reflects confidence that ARS Pharmaceuticals can eventually translate prescription growth into meaningful revenue scale and improved operating leverage, even as the path to profitability remains longer than initially anticipated. However, the single Hold rating serves as a reminder that not all analysts share equal enthusiasm, particularly given the consistent pattern of earnings misses and elevated cash burn rate.

Part 4: Technical Picture

The Barchart Technical Opinion shows a Sell signal at 88%, representing a slight improvement from last week's 100% Sell reading but a significant deterioration from last month's 56% Sell. This indicates mounting technical pressure as the stock approaches earnings, though the recent modest strengthening suggests some stabilization after the sharp year-to-date decline.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum remains negative but less extreme than longer timeframes
• Medium-term (100% Sell): Strong sell signal reflects clear weakness in the intermediate trend as the stock trades well below key moving averages
• Long-term (100% Sell): Maximum bearish reading confirms the sustained downtrend over the past year, with shares down 68% from 52-week highs

Trend Characteristics: The signal strength is rated as "Good" with a "Strengthening" direction, suggesting the technical setup is becoming more defined even as it remains bearish—a pattern that often precedes either a capitulation low or further breakdown.

The stock is trading at $6.05, positioned above its 5-day ($5.92), 10-day ($5.65), and 20-day ($5.95) moving averages, indicating some short-term stabilization. However, it remains well below all longer-term moving averages: the 50-day ($7.68), 100-day ($7.96), and 200-day ($8.81). This configuration—above short-term but below all long-term averages—suggests a potential dead-cat bounce within a broader downtrend rather than a genuine reversal.

The stock is testing resistance at its 20-day moving average of $5.95 while trading near its 52-week low of $6.66, creating a technically precarious setup heading into earnings. The elevated implied volatility of 116.19%—well above the historical volatility of 91.62%—confirms options traders are pricing in significant risk. With the stock below all major long-term moving averages and the technical opinion firmly in sell territory across medium and long-term timeframes, the setup is cautionary for earnings. A positive surprise could trigger a sharp short-covering rally given the oversold conditions, but any disappointment risks accelerating the downtrend toward new lows with limited technical support until the $5.00-$5.35 zone where recent trading activity has clustered.